Credit Suisse’s Biostar Pharmaceuticals, Inc. BSPM Stock Holding History

Credit Suisse’s Portfolio BSPM Stock Details BSPM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-11,023	Closed	-$41K	–	4367
2016 Q3	$41K	Sell	11,023 -18,093	-62%	-$66K	﹤0.01%	4036
2016 Q2	$129K	Buy	+29,116	New	+$64.9K	﹤0.01%	4010

Other funds holding BSPM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Credit Suisse's BSPM Position: Q4 2016 in Review

Credit Suisse sold out of Biostar Pharmaceuticals, Inc. (BSPM) in Q4 2016, closing a stake of 11,023 shares — an estimated $41K sold.

Credit Suisse first reported a position in BSPM in Q2 2016 and held it in 2 quarters. The position peaked at $129K in Q2 2016. 7 funds tracked by Wall St. Rank hold BSPM as of Q4 2016.

Credit Suisse reported no remaining Biostar Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
Credit Suisse sold 11,023 Biostar Pharmaceuticals, Inc. shares in Q4 2016, an estimated $41K.
Credit Suisse first reported a position in Biostar Pharmaceuticals, Inc. in Q2 2016 and held it in 2 quarters.
Credit Suisse's Biostar Pharmaceuticals, Inc. position peaked at $129K in Q2 2016.
7 funds tracked by Wall St. Rank held Biostar Pharmaceuticals, Inc. as of Q4 2016.

Based on Credit Suisse's 13F filing for Q4 2016, filed 14 Feb 2017.